Private Placement

A deepened strategic alliance sees mobility tech provider ECARX invest in Lotus, aiming to accelerate the future of the intelligent, AI-driven cockpit.

With a massive IDR 200 billion capital boost from LDA Capital, Indonesian tech firm NANO is set to execute nearly IDR 5 trillion in contracts.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

A major order for advanced semiconductor equipment will fuel a European firm's expansion, powering next-gen AI data centers and LiDAR systems.

Launching this Christmas, 'The Resurrection Coin' blends faith with Web3 to fund a new film, but faces scrutiny over its regulatory claims.

A cancer research firm is betting its future on Zcash, recruiting the crypto's top minds. Is this the start of institutional adoption for privacy coins?

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

A publicly listed venture builder reports explosive growth and a radical new strategy: using a video game to democratize venture capital for everyone.

Titan Mining's new funding aims to end a 70-year U.S. graphite production gap, a critical move for the nation's EV and energy independence goals.

With a massive capital raise and rapid microreactor progress, NANO Nuclear is positioning itself to power the AI boom and lead a new nuclear renaissance.

WhiteFiber lands a 10-year, 40 MW anchor deal with AI provider Nscale, validating its high-density strategy and fueling North Carolina's tech boom.

As Applied Digital preps its Q2 results, investors watch to see if its multi-billion dollar contracts can quell market volatility and affirm its AI future.

Venture capital giant 500 Global has been selected to help execute the Digital Morocco 2030 strategy, aiming to supercharge the nation's startup ecosystem.

For the first time, Medicare and Medicaid will cover CBD products for senior cancer patients, a landmark decision with massive implications for patients and markets.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

As LunR Royalties begins trading, its parent NGEx Minerals pivots to unlock the potential of its world-class copper-gold assets in South America.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

With a massive potential loan, the U.S. government is backing a plan to mine in Alaska and manufacture in Ohio, aiming to end its reliance on foreign graphite.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?